New vaccine aims to train immune system to attack childhood cancer
NCT ID NCT00911560
First seen Jun 25, 2026 · Last updated Aug 06, 2026 · Updated 3 times
Summary
This trial tests a vaccine designed to help the immune system recognize and attack neuroblastoma, a type of childhood cancer. The vaccine contains two antigens found on neuroblastoma cells, plus an adjuvant to boost the immune response. Participants also take an oral supplement called β-glucan, which may help white blood cells kill cancer. The study includes children with high-risk neuroblastoma who have completed initial treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- bivalent vaccine (GD2L and GD3L antigens linked to KLH) with OPT-821 adjuvant and oral β-glucan
- What this could lead to
- If successful, this vaccine could help the immune system target and kill neuroblastoma cells, potentially improving long-term control of the disease.
- What could go wrong
- This is an early-phase trial (phase I/II) with a small number of participants. The vaccine may not produce a strong enough immune response, or side effects could limit its use.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH-RISK NEUROBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A simple blood test may reveal hidden infertility risk in young cancer survivors
- Can a shorter chemo combo tame High-Risk neuroblastoma?
- Can a radioactive 'Smart Bomb' take down resistant childhood cancers?
- Can AI read tumor slides to outsmart childhood cancer?
- Can a radioated molecule shrink untreatable neuroblastoma?
- Slowing down immunotherapy infusion may reduce pain in children with Tough-to-Treat neuroblastoma